EHA 2016 | The success of Phase III TOWER trial of blinatumomab in ALL
Jae Park
• 9 Jun 2016
Jae Park, MD from Memorial Sloan Kettering Cancer Center, New York, NY discusses current research in acute lymphoblastic leukemia (ALL). Dr Park first discusses the Phase III TOWER study which investigated blinatumomab vs standard of care (NCT02013167), with results showing blinatumomab performing better than conventional therapy. Then Dr Park continued to discuss a second trial on inotuzumab ozogamicin, which also is compared to a standard of care arm. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
